首页 | 官方网站   微博 | 高级检索  
     

^(18)F-FDG符合线路正电子显像评价非小细胞肺癌手术或放化疗疗效价值
引用本文:朱旭生,邹德环,余立群,李镜发. ^(18)F-FDG符合线路正电子显像评价非小细胞肺癌手术或放化疗疗效价值[J]. 河南诊断与治疗杂志, 2014, 0(10): 1019-1021
作者姓名:朱旭生  邹德环  余立群  李镜发
作者单位:广州市第一人民医院核医学科,510180
基金项目:广东省医学科研基金立项资助项目(2011A474); 广州市医药卫生科技一般引导项目(201102A213100); 广东省科技厅2011年立项非资助项目(2011)
摘    要:目的观察非小细胞肺癌患者手术及放、化疗前、后18F-FDG摄取率变化,探讨18 F-FDG符合线路正电子显像在评价非小细胞肺癌手术及放、化疗疗效中的价值。方法 98例非小细胞肺癌患者,其中单纯行手术治疗46例,单纯放疗16例,单纯化疗11例,放疗+化疗25例;手术治疗者分别于术前1周及术后3个月,放疗和/或化疗者分别于放、化疗前1周及放、化疗结束后2个月行18F-FDG符合线路正电子显像,勾画原发灶感兴趣区,计算病灶治疗前摄取比值(R1)与治疗后摄取比值(R2)。结果与组织病理结果进行对照,18 F-FDG符合线路正电子显像治疗前诊断非小细胞肺癌的符合率为100%(98/98);治疗后提示肿瘤残留8例,复发35例,转移27例;不同临床分期、原发灶直径、病理类型患者治疗后R2值均低于治疗前R1值(P〈0.05);临床分期Ⅰ期患者R1值(2.95±0.36)低于Ⅱ、Ⅲ、Ⅳ期患者(4.24±1.38、5.47±1.69、7.51±1.53)(P〈0.05),R2值(0.97±0.12)低于Ⅳ期患者(1.42±0.28)(P〈0.05);原发灶直径≥3cm者R1值(6.13±1.56)高于直径〈3cm者(3.92±1.09)(P〈0.05);鳞癌、腺癌、大细胞癌患者R1、R2值比较差异无统计学意义(P〉0.05)。结论 18 F-FDG符合线路正电子显像在非小细胞肺癌诊断及评估手术及放、化疗疗效中有重要价值;非小细胞肺癌患者18F-FDG摄取比值可能与术前肿瘤分期和原发灶直径有关。

关 键 词:非小细胞肺癌  手术  放疗  化疗  18F-FDG符合线路正电子显像

Value of 18F-FDG coincidence SPECT imaging to evaluating the effect of operation and chemoradiotherapy for non-small cell lung cancer
ZHU Xu-sheng,ZOU De-huan,SHE Li-qun,LI Jing-fa. Value of 18F-FDG coincidence SPECT imaging to evaluating the effect of operation and chemoradiotherapy for non-small cell lung cancer[J]. Henan Journal of Diagnosis and Therapy, 2014, 0(10): 1019-1021
Authors:ZHU Xu-sheng  ZOU De-huan  SHE Li-qun  LI Jing-fa
Affiliation:(Department of Nuclear Medicine, the First People's Hospital of Guangzhou, Guangzhou 510180, China)
Abstract:Objective To explore the value of 18F-FDG coincidence SPECT imaging to evaluating the effect of operation and chemoradiotherapy on non-small cell lung cancer(NSCLC)by observing the changes of 18F-FDG uptake.Methods In98 patients with NSCLC,46 were performed operation,16 received only radiotherapy,11 received only chemotherapy,and 25 received radiotherapy plus chemotherapy.18F-FDG coincidence SPECT imaging was performed one week before and three months after operation,and one week before and two months after chemotherapy and/or radiotherapy.The uptake ratio(R)before and after treatment was calculated by outlining the region of interest of lesions.Results The diagnostic coincidence rate of 18F-FDG before operation to histopathological results was 100%(98/98).18F-FDG showed residual tumor in 8,recurrence in 35,and cancer metastasis in 27 after treatment.R2 after treatment was lower than R1 before treatment in patients with different stages and different diameters of primary focus(P〈0.05).R1 was lower in stageⅠ patients(2.95±0.36)than that in clinical stageⅡ,Ⅲ and Ⅳ patients(4.24±1.38,5.47±1.69,7.51±1.53)(P〈0.05),and R2 was lower(0.97±0.12)than that in stageⅣ patients(1.42±0.28)(P〈0.05).R1 was higher in patients with diameter of primary focus≥3cm(6.13±1.56)than that in patients with diameter of primary focus3cm(3.92±1.09)(P〈0.05).There were no significant differences in R1 and R2in patients with squamous cell carcinoma,adenocarcinoma and large cell carcinoma(P〈0.05).Conclusion 18F-FDG coincidence SPECT plays an important role in the diagnosis of NSCLC and the evaluation of the effect of operation and chemoradiotherapy,and18F-FDG uptake ratio may be correlated with the preoperative tumor staging and the diameter of primary locus.
Keywords:Non-srnall cell lung cancer  surgical treatment  radiotherapy  chemotherapy  18F-FDG
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号